Nathan B Erdmann, Wilton B Williams, Stephen R Walsh, Nicole Grunenberg, Paul T Edlefsen, Paul A Goepfert, Derek W Cain, Kristen W Cohen, Janine Maenza, Kenneth H Mayer, Hong Van Tieu, Magdalena E Sobieszczyk, Edith Swann, Huiyin Lu, Stephen C De Rosa, Zachary Sagawa, M Anthony Moody, Christopher B Fox, Guido Ferrari, R J Edwards, Priyamvada Acharya, S Munir Alam, Robert Parks, Margaret Barr, Georgia D Tomaras, David C Montefiori, Peter B Gilbert, M Juliana McElrath, Lawrence Corey, Barton F Haynes, Lindsey R Baden
BACKGROUND: HIV-1 vaccine development is a global health priority. Broadly neutralizing antibodies (bnAbs) which target the HIV-1 gp41 membrane-proximal external region (MPER) have some of the highest neutralization breadth. An MPER peptide-liposome vaccine has been found to expand bnAb precursors in monkeys. METHODS: The HVTN133 phase 1 clinical trial ( NCT03934541 ) studied the MPER-peptide liposome immunogen in 24 HIV-1 seronegative individuals. Participants were recruited between 15 July 2019 and 18 October 2019 and were randomized in a dose-escalation design to either 500 mcg or 2000 mcg of the MPER-peptide liposome or placebo...
March 18, 2024: medRxiv